FDA Extends Cyramza Approval to Metastatic Non-small Cell Lung Cancer
Lung Cancer, News
The U.S. Food and Drug Administration (FDA) has expanded the use of Cyramza (ramucirumab) to include patients suffering from metastatic non-small cell lung cancer (NSCLC) — the most common type of lung cancer — ... Read more